UK’s CMA Reveals Details Of Fludrocortisone Probe
If the CMA concludes that there has been an infringement, Aspen has agreed to pay £2.1m.
Executive Summary
The UK’s CMA has accused Tiofarma and Amilco of colluding with Aspen over an illegal agreement that resulted in significant price hikes for fludrocortisone.
You may also be interested in...
UK’s CMA Issues Fines Over Fludrocortisone
The UK’s Competition and Markets Authority has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
UK’s CMA Issues Fines Over Fludrocortisone
The UK’s CMA has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
Tiofarma Admits Involvement On UK Fludrocortisone
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.